Centessa Pharmaceuticals (CNTA) Return on Sales (2025)

Centessa Pharmaceuticals (CNTA) reported Return on Sales of 0.13% for Q4 2025, up 18.61% quarter-over-quarter from 0.16% in Q3 2025.

Centessa Pharmaceuticals (CNTA) Return on Sales (2025) Analysis & Trends

Centessa Pharmaceuticals (CNTA) has 1 years of Return on Sales data on file, last reported at 0.13% in Q4 2025.

Return on Sales for Q4 2025 came in at 0.13%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 0.13% (changed N/A YoY), and the FY2025 annual result was 0.13%, changed N/A from the prior year.
Return on Sales improved to 0.13% in Q4 2025 per CNTA's latest filing, from 0.16% in the prior quarter.
Over five years, Return on Sales peaked at 0.02% in Q1 2025 and troughed at 0.16% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.00%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	0.00%
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	0.00%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Centessa Pharmaceuticals	6.15 Bn	6.15 Bn	-	-

Download Data